Cell metabolism under microenvironmental low oxygen tension levels in stemness, proliferation and pluripotency

Current Molecular Medicine

Volumn 15, Issue 4, 2015, Pages 343-359

  De Miguel, M P ^a   Alcaina, Y ^a   De Sainz La Maza, D ^a   Lopez Iglesias, P ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

Author keywords

Cancer; Development; DNA repair; Glycolisis; HIF; Hypoxia; Metabolism; Reprogramming; ROS; Stemness

Indexed keywords

6 PHOSPHOFRUCTO 2 KINASE; BRCA1 PROTEIN; CARBONYL CYANIDE CHLOROPHENYLHYDRAZONE; GELATINASE B; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 3; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1BETA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; KRUPPEL LIKE FACTOR 4; LACTATE DEHYDROGENASE; MACROPHAGE MIGRATION INHIBITION FACTOR; MYC PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; OCTAMER TRANSCRIPTION FACTOR 4; PHOSPHOGLYCERATE DEHYDROGENASE; PHOSPHOGLYCERATE MUTASE; PLATELET DERIVED GROWTH FACTOR; PYRUVATE DEHYDROGENASE KINASE; RAD54 PROTEIN; REACTIVE OXYGEN METABOLITE; SOMATOMEDIN B; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; TRANSFORMING GROWTH FACTOR BETA3; TRANSIENT RECEPTOR POTENTIAL CHANNEL; VASCULOTROPIN; XRCC3 PROTEIN; HOMEODOMAIN PROTEIN; NANOG PROTEIN, HUMAN; OXYGEN; POU5F1 PROTEIN, HUMAN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN; WNT PROTEIN;

ANAEROBIC METABOLISM; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER STEM CELL; CELL DIFFERENTIATION; CELL HYPOXIA; CELL METABOLISM; CELL PROLIFERATION; DNA REPAIR; EMBRYO DEVELOPMENT; GENE EXPRESSION REGULATION; HUMAN; INTRACELLULAR SIGNALING; MICROENVIRONMENT; MITOCHONDRIAL RESPIRATION; NUCLEAR REPROGRAMMING; OXIDATIVE PHOSPHORYLATION; OXYGEN TENSION; PLURIPOTENT STEM CELL; PROTEIN EXPRESSION; REGULATORY MECHANISM; STEM CELL NICHE; UNFOLDED PROTEIN RESPONSE; WALKER WARBURG SYNDROME; ANOXIA; BIOSYNTHESIS; GENETICS; GLYCOLYSIS; METABOLISM; MITOCHONDRION; NEOPLASM; PHYSIOLOGY;

IPS;

ANOXIA; CELL DIFFERENTIATION; CELL HYPOXIA; CELL PROLIFERATION; DNA REPAIR; EMBRYONIC DEVELOPMENT; GLYCOLYSIS; HOMEODOMAIN PROTEINS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MITOCHONDRIA; NEOPLASMS; NEOPLASTIC STEM CELLS; OCTAMER TRANSCRIPTION FACTOR-3; OXIDATIVE PHOSPHORYLATION; OXYGEN; PLURIPOTENT STEM CELLS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WNT PROTEINS;

EID: 84930977402     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/1566524015666150505160406     Document Type: Article

References (174)

1. [1] Simon MC, Keith B. The role of oxygen availability in embryonic development and stem cell function. Nat Rev Mol Cell Biol 2008; 9: 285-96.
2. [2] Carreau A, El Hafny-Rahbi B, Matejuk A, Grillon C, Kieda C. Why is the partial oxygen pressure of human tissues a crucial parameter? Small molecules and hypoxia. J Cell Mol Med 2011; 15: 1239-53.
3. [3] Dewhirst MW, Ong ET, Rosner GL, et al. Arteriolar oxygenation in tumour and subcutaneous arterioles: effects of inspired air oxygen content. Br J Cancer Suppl 1996; 27: S241-6.
4. [4] Parmar K, Mauch P, Vergilio JA, Sackstein R, Down JD. Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia. Proc Natl Acad Sci U S A 2007; 104: 5431-6.
5. [5] Quinn P, Harlow GM. The effect of oxygen on the development of preimplantation mouse embryos in vitro. J Exp Zool 1978; 206: 73-80.
6. [6] Morriss GM, New DA. Effect of oxygen concentration on morphogenesis of cranial neural folds and neural crest in cultured rat embryos. J Embryol Exp Morphol 1979; 54: 17-35.
7. [7] Ezashi T, Das P, Roberts RM. Low O2 tensions and the prevention of differentiation of hES cells. Proc Natl Acad Sci U S A 2005; 102: 4783-8.
8. [8] Fischer B, Bavister BD. Oxygen tension in the oviduct and uterus of rhesus monkeys, hamsters and rabbits. J Reprod Fertil 1993; 99: 673-9.
9. [9] Genbacev O, Zhou Y, Ludlow JW, Fisher SJ. Regulation of human placental development by oxygen tension. Science 1997; 277: 1669-72.
10. [10] Caniggia I, Mostachfi H, Winter J, et al. Hypoxia-inducible factor-1 mediates the biological effects of oxygen on human trophoblast differentiation through TGFbeta(3). J Clin Invest 2000; 105: 577-87.
11. [11] Aplin JD. Hypoxia and human placental development. J Clin Invest 2000; 105: 559-60.
12. [12] Forsythe JA, Jiang BH, Iyer NV, et al. Activation of vascular endothelial growth factor gene transcription by hypoxiainducible factor 1. Mol Cell Biol 1996; 16: 4604-13.
13. [13] Provot S, Zinyk D, Gunes Y, et al. Hif-1alpha regulates differentiation of limb bud mesenchyme and joint development. J Cell Biol 2007; 177: 451-64.
14. [14] Nunn AV, Bell J, Barter P. The integration of lipid-sensing and anti-inflammatory effects: how the PPARs play a role in metabolic balance. Nucl Recept 2007; 5: 1.
15. [15] Nakamura Y, Hinoi E, Iezaki T, et al. Repression of adipogenesis through promotion of Wnt/beta-catenin signaling by TIS7 up-regulated in adipocytes under hypoxia. Biochim Biophys Acta 2013; 1832: 1117-28.
16. [16] Park YK, Park B, Lee S, et al. Hypoxia-inducible factor-2alpha-dependent hypoxic induction of Wnt10b expression in adipogenic cells. J Biol Chem 2013; 288: 26311-22.
17. [17] Cipolleschi MG, Dello Sbarba P, Olivotto M. The role of hypoxia in the maintenance of hematopoietic stem cells. Blood 1993; 82: 2031-7.
18. [18] Hass R, Kasper C, Bohm S, Jacobs R. Different populations and sources of human mesenchymal stem cells (MSC): A comparison of adult and neonatal tissue-derived MSC. Cell Commun Signal 2011; 9: 12.
19. [19] Kimura W, Sadek HA. The cardiac hypoxic niche: emerging role of hypoxic microenvironment in cardiac progenitors. Cardiovasc Diagn Ther 2012; 2: 278-89.
20. [20] Dakubo GD. The Warburg Phenomenon and Other Metabolic Alterations of Cancer Cells. Mitochondrial Genetics and Cancer. Springer Berlin Heidelberg. 2010; pp. 39-66.
21. [21] Warburg O. On respiratory impairment in cancer cells. Science 1956; 124: 269-70.
22. [22] Boland ML, Chourasia AH, Macleod KF. Mitochondrial Dysfunction in Cancer. Front Oncol 2013; 3: 292.
23. [23] Ayyasamy V, Owens KM, Desouki MM, et al. Cellular model of Warburg effect identifies tumor promoting function of UCP2 in breast cancer and its suppression by genipin. PLoS One 2011; 6: e24792.
24. [24] Lehninger AL, Nelson DL, Cox MM. Principles of Biochemistry; 2nd edition. Worth, New York. 1993; pp. 114.
25. [25] Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell 2012; 21: 297-308.
26. [26] Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009; 324: 1029-33.
27. [27] Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74.
28. [28] Gradin K, McGuire J, Wenger RH, et al. Functional interference between hypoxia and dioxin signal transduction pathways: competition for recruitment of the Arnt transcription factor. Mol Cell Biol 1996; 16: 5221-31.
29. [29] Majmundar AJ, Wong WJ, Simon MC. Hypoxia-inducible factors and the response to hypoxic stress. Mol Cell 2010; 40: 294-309.
30. [30] Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxiainducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A 1995; 92: 5510-4.
31. [31] Carrero P, Okamoto K, Coumailleau P, et al. Redoxregulated recruitment of the transcriptional coactivators CREB-binding protein and SRC-1 to hypoxia-inducible factor 1alpha. Mol Cell Biol 2000; 20: 402-15.
32. [32] Ruas JL, Poellinger L. Hypoxia-dependent activation of HIF into a transcriptional regulator. Semin Cell Dev Biol 2005; 16: 514-22.
33. [33] Kaluz S, Kaluzova M, Stanbridge EJ. Regulation of gene expression by hypoxia: integration of the HIF-transduced hypoxic signal at the hypoxia-responsive element. Clin Chim Acta 2008; 395: 6-13.
34. [34] Wang V, Davis DA, Haque M, Huang LE, Yarchoan R. Differential gene up-regulation by hypoxia-inducible factor-1alpha and hypoxia-inducible factor-2alpha in HEK293T cells. Cancer Res 2005; 65: 3299-306.
35. [35] Bertout JA, Patel SA, Simon MC. The impact of O2 availability on human cancer. Nat Rev Cancer 2008; 8: 967-75.
36. [36] Heikkila M, Pasanen A, Kivirikko KI, Myllyharju J. Roles of the human hypoxia-inducible factor (HIF)-3alpha variants in the hypoxia response. Cell Mol Life Sci 2011; 68: 3885-901.
37. [37] Maynard MA, Evans AJ, Hosomi T, et al. Human HIF-3alpha4 is a dominant-negative regulator of HIF-1 and is down-regulated in renal cell carcinoma. FASEB J 2005; 19: 1396-406.
38. [38] Maynard MA, Evans AJ, Shi W, et al. Dominant-negative HIF-3 alpha 4 suppresses VHL-null renal cell carcinoma progression. Cell Cycle 2007; 6: 2810-6.
39. [39] Aprelikova O, Wood M, Tackett S, Chandramouli GV, Barrett JC. Role of ETS transcription factors in the hypoxia-inducible factor-2 target gene selection. Cancer Res 2006; 66: 5641-7.
40. [40] Kotch LE, Iyer NV, Laughner E, Semenza GL. Defective vascularization of HIF-1alpha-null embryos is not associated with VEGF deficiency but with mesenchymal cell death. Dev Biol 1999; 209: 254-67.
41. [41] Tian H, Hammer RE, Matsumoto AM, Russell DW, McKnight SL. The hypoxia-responsive transcription factor EPAS1 is essential for catecholamine homeostasis and protection against heart failure during embryonic development. Genes Dev 1998; 12: 3320-4.
42. [42] Covello KL, Kehler J, Yu H, et al. HIF-2alpha regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth. Genes Dev 2006; 20: 557-70.
43. [43] Elvert G, Kappel A, Heidenreich R, et al. Cooperative interaction of hypoxia-inducible factor-2alpha (HIF-2alpha) and Ets-1 in the transcriptional activation of vascular endothelial growth factor receptor-2 (Flk-1). J Biol Chem 2003; 278: 7520-30.
44. [44] Semenza GL. Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci 2012; 33: 207-14.
45. [45] Sharp FR, Ran R, Lu A, et al. Hypoxic preconditioning protects against ischemic brain injury. NeuroRx 2004; 1: 26-35.
46. [46] Kaelin WG, Jr. The von Hippel-Lindau gene, kidney cancer, and oxygen sensing. J Am Soc Nephrol 2003; 14: 2703-11.
47. [47] Kamura T, Sato S, Iwai K, et al. Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc Natl Acad Sci U S A 2000; 97: 10430-5.
48. [48] Kondo K, Kaelin WG, Jr. The von Hippel-Lindau tumor suppressor gene. Exp Cell Res 2001; 264: 117-25.
49. [49] Brahimi-Horn MC, Chiche J, Pouyssegur J. Hypoxia signalling controls metabolic demand. Curr Opin Cell Biol 2007; 19: 223-9.
50. [50] Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999; 399: 271-5.
51. [51] Salceda S, Caro J. Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitinproteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem 1997; 272: 22642-7.
52. [52] Lando D, Peet DJ, Whelan DA, Gorman JJ, Whitelaw ML. Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science 2002; 295: 858-61.
53. [53] Webb JD, Coleman ML, Pugh CW. Hypoxia, hypoxiainducible factors (HIF), HIF hydroxylases and oxygen sensing. Cell Mol Life Sci 2009; 66: 3539-54.
54. [54] Mahon PC, Hirota K, Semenza GL. FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev 2001; 15: 2675-86.
55. [55] Koivunen P, Hirsila M, Gunzler V, Kivirikko KI, Myllyharju J. Catalytic properties of the asparaginyl hydroxylase (FIH) in the oxygen sensing pathway are distinct from those of its prolyl 4-hydroxylases. J Biol Chem 2004; 279: 9899-904.
56. [56] Peet DJ, Lando D, Whelan DA, Whitelaw ML, Gorman JJ. Oxygen-dependent asparagine hydroxylation. Methods Enzymol 2004; 381: 467-87.
57. [57] Zhang N, Fu Z, Linke S, et al. The asparaginyl hydroxylase factor inhibiting HIF-1alpha is an essential regulator of metabolism. Cell Metab 2010; 11: 364-78.
58. [58] Lum JJ, Bui T, Gruber M, et al. The transcription factor HIF-1alpha plays a critical role in the growth factor-dependent regulation of both aerobic and anaerobic glycolysis. Genes Dev 2007; 21: 1037-49.
59. [59] Kaelin WG, Jr. ROS: really involved in oxygen sensing. Cell Metab 2005; 1: 357-8.
60. [60] Dioum EM, Chen R, Alexander MS, et al. Regulation of hypoxia-inducible factor 2alpha signaling by the stressresponsive deacetylase sirtuin 1. Science 2009; 324: 1289-93.
61. [61] Lim JH, Lee YM, Chun YS, et al. Sirtuin 1 modulates cellular responses to hypoxia by deacetylating hypoxia-inducible factor 1alpha. Mol Cell 2010; 38: 864-78.
62. [62] Zhong L, D'Urso A, Toiber D, et al. The histone deacetylase Sirt6 regulates glucose homeostasis via Hif1alpha. Cell 2010; 140: 280-93.
63. [63] Isaacs JS, Jung YJ, Mole DR, et al. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell 2005; 8: 143-53.
64. [64] Selak MA, Armour SM, MacKenzie ED, et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 2005; 7: 77-85.
65. [65] Lu H, Dalgard CL, Mohyeldin A, et al. Reversible inactivation of HIF-1 prolyl hydroxylases allows cell metabolism to control basal HIF-1. J Biol Chem 2005; 280: 41928-39.
66. [66] Pedersen M, Lofstedt T, Sun J, et al. Stem cell factor induces HIF-1alpha at normoxia in hematopoietic cells. Biochem Biophys Res Commun 2008; 377: 98-103.
67. [67] Sanchez M, Galy B, Muckenthaler MU, Hentze MW. Ironregulatory proteins limit hypoxia-inducible factor-2alpha expression in iron deficiency. Nat Struct Mol Biol 2007; 14: 420-6.
68. [68] Manalo DJ, Rowan A, Lavoie T, et al. Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood 2005; 105: 659-69.
69. [69] Lee JW, Bae SH, Jeong JW, Kim SH, Kim KW. Hypoxiainducible factor (HIF-1)alpha: its protein stability and biological functions. Exp Mol Med 2004; 36: 1-12.
70. [70] Semenza GL. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med 2002; 8: S62-7.
71. [71] Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3: 721-32.
72. [72] Zbytek B, Peacock DL, Seagroves TN, Slominski A. Putative role of HIF transcriptional activity in melanocytes and melanoma biology. Dermatoendocrinol 2013; 5: 239-51.
73. [73] Arany Z, Foo SY, Ma Y, et al. HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1alpha. Nature 2008; 451: 1008-12.
74. [74] Mizukami Y, Kohgo Y, Chung DC. Hypoxia inducible factor-1 independent pathways in tumor angiogenesis. Clin Cancer Res 2007; 13: 5670-4.
75. [75] Arsham AM, Howell JJ, Simon MC. A novel hypoxiainducible factor-independent hypoxic response regulating mammalian target of rapamycin and its targets. J Biol Chem 2003; 278: 29655-60.
76. [76] Liu L, Cash TP, Jones RG, et al. Hypoxia-induced energy stress regulates mRNA translation and cell growth. Mol Cell 2006; 21: 521-31.
77. [77] Ron D, Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol 2007; 8: 519-29.
78. [78] Koumenis C, Wouters BG. "Translating" tumor hypoxia: unfolded protein response (UPR)-dependent and UPRindependent pathways. Mol Cancer Res 2006; 4: 423-36.
79. [79] Wouters BG, Koritzinsky M. Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat Rev Cancer 2008; 8: 851-64.
80. [80] Dever TE. Gene-specific regulation by general translation factors. Cell 2002; 108: 545-56.
81. [81] Vagner S, Galy B, Pyronnet S. Irresistible IRES. Attracting the translation machinery to internal ribosome entry sites. EMBO Rep 2001; 2: 893-8.
82. [82] Bornes S, Prado-Lourenco L, Bastide A, et al. Translational induction of VEGF internal ribosome entry site elements during the early response to ischemic stress. Circ Res 2007; 100: 305-8.
83. [83] Hu CJ, Iyer S, Sataur A, et al. Differential regulation of the transcriptional activities of hypoxia-inducible factor 1 alpha (HIF-1alpha) and HIF-2alpha in stem cells. Mol Cell Biol 2006; 26: 3514-26.
84. [84] Hochachka PW, Lutz PL. Mechanism, origin, and evolution of anoxia tolerance in animals. Comp Biochem Physiol B Biochem Mol Biol 2001; 130: 435-59.
85. [85] Illsley NP, Caniggia I, Zamudio S. Placental metabolic reprogramming: do changes in the mix of energy-generating substrates modulate fetal growth? Int J Dev Biol 2010; 54: 409-19.
86. [86] Erusalimsky JD, Moncada S. Nitric oxide and mitochondrial signaling: from physiology to pathophysiology. Arterioscler Thromb Vasc Biol 2007; 27: 2524-31.
87. [87] Hagen T, Taylor CT, Lam F, Moncada S. Redistribution of intracellular oxygen in hypoxia by nitric oxide: effect on HIF1alpha. Science 2003; 302: 1975-8.
88. [88] Abe H, Ishikawa W, Kushima T, et al. Nitric oxide induces vascular endothelial growth factor expression in the rat placenta in vivo and in vitro. Biosci Biotechnol Biochem 2013; 77: 971-6.
89. [89] Cullis ER, Kalber TL, Ashton SE, et al. Tumour overexpression of inducible nitric oxide synthase (iNOS) increases angiogenesis and may modulate the anti-tumour effects of the vascular disrupting agent ZD6126. Microvasc Res 2006; 71: 76-84.
90. [90] Dahia PL, Ross KN, Wright ME, et al. A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genet 2005; 1: 72-80.
91. [91] Kim JW, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 2006; 3: 177-85.
92. [92] Papandreou I, Cairns RA, Fontana L, Lim AL, Denko NC. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab 2006; 3: 187-97.
93. [93] Firth JD, Ebert BL, Ratcliffe PJ. Hypoxic regulation of lactate dehydrogenase A. Interaction between hypoxia-inducible factor 1 and cAMP response elements. J Biol Chem 1995; 270: 21021-7.
94. [94] Zhang H, Gao P, Fukuda R, et al. HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHLdeficient renal cell carcinoma by repression of C-MYC activity. Cancer Cell 2007; 11: 407-20.
95. [95] Hamacher-Brady A, Brady NR, Logue SE, et al. Response to myocardial ischemia/reperfusion injury involves Bnip3 and autophagy. Cell Death Differ 2007; 14: 146-57.
96. [96] Yan L, Vatner DE, Kim SJ, et al. Autophagy in chronically ischemic myocardium. Proc Natl Acad Sci U S A 2005; 102: 13807-12.
97. [97] Zhu H, Tannous P, Johnstone JL, et al. Cardiac autophagy is a maladaptive response to hemodynamic stress. J Clin Invest 2007; 117: 1782-93.
98. [98] Zhang H, Bosch-Marce M, Shimoda LA, et al. Mitochondrial autophagy is an HIF-1-dependent adaptive metabolic response to hypoxia. J Biol Chem 2008; 283: 10892-903.
99. [99] Lee SH, Heo JS, Han HJ. Effect of hypoxia on 2-deoxyglucose uptake and cell cycle regulatory protein expression of mouse embryonic stem cells: involvement of Ca2+ /PKC, MAPKs and HIF-1alpha. Cell Physiol Biochem 2007; 19: 269-82.
100. [100] Jeong CH, Lee HJ, Cha JH, et al. Hypoxia-inducible factor-1 alpha inhibits self-renewal of mouse embryonic stem cells in Vitro via negative regulation of the leukemia inhibitory factor-STAT3 pathway. J Biol Chem 2007; 282: 13672-9.
101. [101] Gordan JD, Bertout JA, Hu CJ, Diehl JA, Simon MC. HIF-2alpha promotes hypoxic cell proliferation by enhancing cmyc transcriptional activity. Cancer Cell 2007; 11: 335-47.
102. [102] Koshiji M, Kageyama Y, Pete EA, et al. HIF-1alpha induces cell cycle arrest by functionally counteracting Myc. EMBO J 2004; 23: 1949-56.
103. [103] To KK, Sedelnikova OA, Samons M, Bonner WM, Huang LE. The phosphorylation status of PAS-B distinguishes HIF-1alpha from HIF-2alpha in NBS1 repression. EMBO J 2006; 25: 4784-94.
104. [104] Yoo YG, Hayashi M, Christensen J, Huang LE. An essential role of the HIF-1alpha-c-Myc axis in malignant progression. Ann N Y Acad Sci 2009; 1177: 198-204.
105. [105] Kim WY, Perera S, Zhou B, et al. HIF2alpha cooperates with RAS to promote lung tumorigenesis in mice. J Clin Invest 2009; 119: 2160-70.
106. [106] Franovic A, Holterman CE, Payette J, Lee S. Human cancers converge at the HIF-2alpha oncogenic axis. Proc Natl Acad Sci U S A 2009; 106: 21306-11.
107. [107] Moore KA, Lemischka IR. Stem cells and their niches. Science 2006; 311: 1880-5.
108. [108] Diabira S, Morandi X. Gliomagenesis and neural stem cells: Key role of hypoxia and concept of tumor "neo-niche". Med Hypotheses 2008; 70: 96-104.
109. [109] Westfall SD, Sachdev S, Das P, et al. Identification of oxygen-sensitive transcriptional programs in human embryonic stem cells. Stem Cells Dev 2008; 17: 869-81.
110. [110] Lengner CJ, Gimelbrant AA, Erwin JA, et al. Derivation of pre-X inactivation human embryonic stem cells under physiological oxygen concentrations. Cell 2010; 141: 872-83.
111. [111] Mandal S, Lindgren AG, Srivastava AS, Clark AT, Banerjee U. Mitochondrial function controls proliferation and early differentiation potential of embryonic stem cells. Stem Cells 2011; 29: 486-95.
112. [112] Forristal CE, Wright KL, Hanley NA, Oreffo RO, Houghton FD. Hypoxia inducible factors regulate pluripotency and proliferation in human embryonic stem cells cultured at reduced oxygen tensions. Reproduction 2010; 139: 85-97.
113. [113] Gustafsson MV, Zheng X, Pereira T, et al. Hypoxia requires notch signaling to maintain the undifferentiated cell state. Dev Cell 2005; 9: 617-28.
114. [114] Axelson H, Fredlund E, Ovenberger M, Landberg G, Pahlman S. Hypoxia-induced dedifferentiation of tumor cells--a mechanism behind heterogeneity and aggressiveness of solid tumors. Semin Cell Dev Biol 2005; 16: 554-63.
115. [115] Keith B, Johnson RS, Simon MC. HIF1alpha and HIF2alpha: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer 2012; 12: 9-22.
116. [116] Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131: 861-72.
117. [117] Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126: 663-76.
118. [118] Yu J, Hu K, Smuga-Otto K, et al. Human induced pluripotent stem cells free of vector and transgene sequences. Science 2009; 324: 797-801.
119. [119] Yoshida Y, Takahashi K, Okita K, Ichisaka T, Yamanaka S. Hypoxia enhances the generation of induced pluripotent stem cells. Cell Stem Cell 2009; 5: 237-41.
120. [120] Shimada H, Hashimoto Y, Nakada A, Shigeno K, Nakamura T. Accelerated generation of human induced pluripotent stem cells with retroviral transduction and chemical inhibitors under physiological hypoxia. Biochem Biophys Res Commun 2012; 417: 659-64.
121. [121] Medley TL, Furtado M, Lam NT, et al. Effect of oxygen on cardiac differentiation in mouse iPS cells: role of hypoxia inducible factor-1 and Wnt/beta-catenin signaling. PLoS One 2013; 8: e80280.
122. [122] Panopoulos AD, Yanes O, Ruiz S, et al. The metabolome of induced pluripotent stem cells reveals metabolic changes occurring in somatic cell reprogramming. Cell Res 2012; 22: 168-77.
123. [123] Zhang J, Nuebel E, Daley GQ, Koehler CM, Teitell MA. Metabolic regulation in pluripotent stem cells during reprogramming and self-renewal. Cell Stem Cell 2012; 11: 589-95.
124. [124] Folmes CD, Nelson TJ, Martinez-Fernandez A, et al. Somatic oxidative bioenergetics transitions into pluripotencydependent glycolysis to facilitate nuclear reprogramming. Cell Metab 2011; 14: 264-71.
125. [125] Zhu S, Li W, Zhou H, et al. Reprogramming of human primary somatic cells by OCT4 and chemical compounds. Cell Stem Cell 2010; 7: 651-5.
126. [126] Mathieu J, Zhang Z, Nelson A, et al. Hypoxia induces reentry of committed cells into pluripotency. Stem Cells 2013; 31: 1737-48.
127. [127] Lopez-Iglesias P, Alcaina Y, Tapia N, et al. Hypoxia Induces Pluripotency in Primordial Germ Cells by HIF1alpha Stabilization and Oct4 Deregulation. Antioxid Redox Signal 2015; 22: 205-23.
128. [128] Kaelin WG, Jr. The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. Nat Rev Cancer 2008; 8: 865-73.
129. [129] Semenza GL. Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov Today 2007; 12: 853-9.
130. [130] Shay JE, Imtiyaz HZ, Sivanand S, et al. Inhibition of hypoxiainducible factors limits tumor progression in a mouse model of colorectal cancer. Carcinogenesis 2014; 35: 1067-77.
131. [131] Huang X, Ding L, Bennewith KL, et al. Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation. Mol Cell 2009; 35: 856-67.
132. [132] Heddleston JM, Li Z, Lathia JD, et al. Hypoxia inducible factors in cancer stem cells. Br J Cancer 2010; 102: 789-95.
133. [133] Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-11.
134. [134] Sarkar FH, Li Y, Wang Z, Kong D. Pancreatic cancer stem cells and EMT in drug resistance and metastasis. Minerva Chir 2009; 64: 489-500.
135. [135] Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006; 444: 756-60.
136. [136] Krivtsov AV, Twomey D, Feng Z, et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 2006; 442: 818-22.
137. [137] Jogi A, Ora I, Nilsson H, et al. Hypoxia alters gene expression in human neuroblastoma cells toward an immature and neural crest-like phenotype. Proc Natl Acad Sci U S A 2002; 99: 7021-6.
138. [138] McCord AM, Jamal M, Shankavaram UT, et al. Physiologic oxygen concentration enhances the stem-like properties of CD133+ human glioblastoma cells in vitro. Mol Cancer Res 2009; 7: 489-97.
139. [139] Silvan U, Diez-Torre A, Arluzea J, et al. Hypoxia and pluripotency in embryonic and embryonal carcinoma stem cell biology. Differentiation 2009; 78: 159-68.
140. [140] Bao B, Ahmad A, Kong D, et al. Hypoxia induced aggressiveness of prostate cancer cells is linked with deregulated expression of VEGF, IL-6 and miRNAs that are attenuated by CDF. PLoS One 2012; 7: e43726.
141. [141] Bao B, Ali S, Kong D, et al. Anti-tumor activity of a novel compound-CDF is mediated by regulating miR-21, miR-200, and PTEN in pancreatic cancer. PLoS One 2011; 6: e17850.
142. [142] Moriyama T, Ohuchida K, Mizumoto K, et al. MicroRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance. Mol Cancer Ther 2009; 8: 1067-74.
143. [143] Liu LZ, Li C, Chen Q, et al. MiR-21 induced angiogenesis through AKT and ERK activation and HIF-1alpha expression. PLoS One 2011; 6: e19139.
144. [144] Riggs JW, Barrilleaux BL, Varlakhanova N, et al. Induced pluripotency and oncogenic transformation are related processes. Stem Cells Dev 2013; 22: 37-50.
145. [145] Mathieu J, Zhang Z, Zhou W, et al. HIF induces human embryonic stem cell markers in cancer cells. Cancer Res 2011; 71: 4640-52.
146. [146] Gordan JD, Thompson CB, Simon MC. HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation. Cancer Cell 2007; 12: 108-13.
147. [147] An WG, Kanekal M, Simon MC, et al. Stabilization of wildtype p53 by hypoxia-inducible factor 1alpha. Nature 1998; 392: 405-8.
148. [148] Aminova LR, Siddiq A, Ratan RR. Antioxidants, HIF prolyl hydroxylase inhibitors or short interfering RNAs to BNIP3 or PUMA, can prevent prodeath effects of the transcriptional activator, HIF-1alpha, in a mouse hippocampal neuronal line. Antioxid Redox Signal 2008; 10: 1989-98.
149. [149] Ravi R, Mookerjee B, Bhujwalla ZM, et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxiainducible factor 1alpha. Genes Dev 2000; 14: 34-44.
150. [150] Sermeus A, Genin M, Maincent A, et al. Hypoxia-induced modulation of apoptosis and BCL-2 family proteins in different cancer cell types. PLoS One 2012; 7: e47519.
151. [151] Chen N, Chen X, Huang R, et al. BCL-xL is a target gene regulated by hypoxia-inducible factor-1{alpha}. J Biol Chem 2009; 284: 10004-12.
152. [152] Cosse JP, Rommelaere G, Ninane N, Arnould T, Michiels C. BNIP3 protects HepG2 cells against etoposide-induced cell death under hypoxia by an autophagy-independent pathway. Biochem Pharmacol 2010; 80: 1160-9.
153. [153] Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature 2009; 461: 1071-8.
154. [154] Cimprich KA, Cortez D. ATR: an essential regulator of genome integrity. Nat Rev Mol Cell Biol 2008; 9: 616-27.
155. [155] Ciccia A, Elledge SJ. The DNA damage response: making it safe to play with knives. Mol Cell 2010; 40: 179-204.
156. [156] Heddleston JM, Li Z, McLendon RE, Hjelmeland AB, Rich JN. The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle 2009; 8: 3274-84.
157. [157] Olcina MM, Hammond EM. Hypoxia and the DNA Damage Response. In: Melillo G, editor. Hypoxia and Cancer: Biological Implications and Therapeutic Opportunities: Springer Science & Business Media. 2013; pp. 377.
158. [158] Rohwer N, Zasada C, Kempa S, Cramer T. The growing complexity of HIF-1alpha's role in tumorigenesis: DNA repair and beyond. Oncogene 2013; 32: 3569-76.
159. [159] Cam H, Easton JB, High A, Houghton PJ. mTORC1 signaling under hypoxic conditions is controlled by ATM-dependent phosphorylation of HIF-1alpha. Mol Cell 2010; 40: 509-20.
160. [160] Elser M, Borsig L, Hassa PO, et al. Poly(ADP-ribose) polymerase 1 promotes tumor cell survival by coactivating hypoxia-inducible factor-1-dependent gene expression. Mol Cancer Res 2008; 6: 282-90.
161. [161] Wirthner R, Wrann S, Balamurugan K, Wenger RH, Stiehl DP. Impaired DNA double-strand break repair contributes to chemoresistance in HIF-1 alpha-deficient mouse embryonic fibroblasts. Carcinogenesis 2008; 29: 2306-16.
162. [162] Yatabe N, Kyo S, Maida Y, et al. HIF-1-mediated activation of telomerase in cervical cancer cells. Oncogene 2004; 23: 3708-15.
163. [163] Bouquet F, Ousset M, Biard D, et al. A DNA-dependent stress response involving DNA-PK occurs in hypoxic cells and contributes to cellular adaptation to hypoxia. J Cell Sci 2011; 124: 1943-51.
164. [164] Glazer PM, Hegan DC, Lu Y, Czochor J, Scanlon SE. Hypoxia and DNA repair. Yale J Biol Med 2013; 86: 443-51.
165. [165] Pires IM, Olcina MM, Anbalagan S, et al. Targeting radiationresistant hypoxic tumour cells through ATR inhibition. Br J Cancer 2012; 107: 291-9.
166. [166] Hegan DC, Lu Y, Stachelek GC, et al. Inhibition of poly(ADPribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130. Proc Natl Acad Sci U S A 2010; 107: 2201-6.
167. [167] Chan N, Koritzinsky M, Zhao H, et al. Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance. Cancer Res 2008; 68: 605-14.
168. [168] Crosby ME, Devlin CM, Glazer PM, Calin GA, Ivan M. Emerging roles of microRNAs in the molecular responses to hypoxia. Curr Pharm Des 2009; 15: 3861-6.
169. [169] Facucho-Oliveira JM, St John JC. The relationship between pluripotency and mitochondrial DNA proliferation during early embryo development and embryonic stem cell differentiation. Stem Cell Rev 2009; 5: 140-58.
170. [170] Rocha CR, Lerner LK, Okamoto OK, Marchetto MC, Menck CF. The role of DNA repair in the pluripotency and differentiation of human stem cells. Mutat Res 2013; 752: 25-35.
171. [171] Nagaria P, Robert C, Rassool FV. DNA double-strand break response in stem cells: mechanisms to maintain genomic integrity. Biochim Biophys Acta 2013; 1830: 2345-53.
172. [172] Gore A, Li Z, Fung HL, et al. Somatic coding mutations in human induced pluripotent stem cells. Nature 2011; 471: 63-7.
173. [173] Luo LZ, Gopalakrishna-Pillai S, Nay SL, et al. DNA repair in human pluripotent stem cells is distinct from that in nonpluripotent human cells. PLoS One 2012; 7: e30541.
174. [174] Maynard S, Swistowska AM, Lee JW, et al. Human embryonic stem cells have enhanced repair of multiple forms of DNA damage. Stem Cells 2008; 26: 2266-74.